Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $177.00.

A number of equities research analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th.

Read Our Latest Stock Report on Jazz Pharmaceuticals

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,253 shares of company stock worth $1,001,434. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC lifted its position in shares of Jazz Pharmaceuticals by 1,808.4% in the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after purchasing an additional 427,246 shares during the period. Wedge Capital Management L L P NC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $32,497,000. Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares during the period. Point72 Asset Management L.P. boosted its position in Jazz Pharmaceuticals by 20,323.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 182,015 shares of the specialty pharmaceutical company’s stock valued at $19,427,000 after acquiring an additional 182,915 shares in the last quarter. Finally, Cinctive Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $14,277,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $124.39 on Tuesday. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $7.52 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The firm’s 50 day simple moving average is $122.37 and its 200 day simple moving average is $115.45.

Jazz Pharmaceuticals Company Profile

(Get Free Report

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.